No Data
No Data
A. G. P. Maintains Akari Therapeutics(AKTX.US) With Buy Rating, Cuts Target Price to $7
Akari Therapeutics Price Target Raised to $7 From $4 at Alliance Global
Express News | Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
Express News | Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
Akari Therapeutics | 8-K: Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update